Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
NCT07931547· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954· Phase 2· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· Phase 2· TG Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886· Phase 3· Eli Lilly and Company· Source
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma
2024-514635-26-00· Phase 3· Medical University Of Gdansk· Source
Active, not recruiting
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724· Phase 3· Sandoz· Source
Active, not recruiting
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247· Phase 3· Cartesian Therapeutics· Source
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289· Phase 3· Takeda· Source
Recruiting
Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.
2024-518316-39-00· Phase 2/3· Medical University Of Lodz· Source
Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383· Phase 4· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Active, not recruiting
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases
2023-509555-13-00· Phase 1· Tg Therapeutics Inc.· Source
Active, not recruiting
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· Phase 3· Celltrion Inc.· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667· Phase 3· Eli Lilly and Company· Source
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963· Phase 3· TG Therapeutics, Inc.· Source
Active, not recruiting
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
NCT05723835· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD)
2024-516714-37-00· Phase 3· Medical University Of Bialystok· Source
Active, not recruiting
Cladribine therapy in Myasthenia
2024-517083-32-00· Phase 2· Uniwersytet Medyczny W Lublinie· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361· Phase 1· Hoffmann-La Roche· Source
Active, not recruiting
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia -
A randomized phase III study conducted in agreement with the AIEOP-BFM study group
2024-517253-27-00· Phase 3· Medical University Of Silesia Katowice Poland· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997· Phase 3· TG Therapeutics, Inc.· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS
2023-507906-15-00· Phase 3· Novartis Pharma AG· Source
Active, not recruiting
Paediatric Hepatic International Tumour Trial
NCT03017326· Phase 3· University of Birmingham· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source